Cinclus Pharma Holding AB announced that it expects to receive SEK 240 million in funding from Trill Impact AB, Eir Ventures, Irrus Investments Nominee Limited, AP Fonden 4, Linc AB

Cinclus Pharma Holding AB announced a private placement of SEK 240 million led by Trill Impact AB on April 19, 2022. The transaction will include participation from Eir Ventures I AB, a fund managed by Eir Ventures, Irrus Investments Nominee Limited, Linc AB and existing investor, AP Fonden 4. As part of the transaction, Nina Rawal from Trill Impact AB will join company's board of directors. The transaction has been approved in the extraordinary general meeting of the company.